132 related articles for article (PubMed ID: 4096253)
21. [Research regarding the action of a derivative of the clofibric acid series on lipid metabolism].
Filip M; Păduraru I; Hriscu A; Neacşu R; Dănilă G; Filip F
Rev Med Chir Soc Med Nat Iasi; 1987; 91(2):341-5. PubMed ID: 3685700
[No Abstract] [Full Text] [Related]
22. [Therapeutic effects of bezafibrate in hyperlipidemia].
Kunesová M; Honková M; Zeman M; Mares P; Skorepa J
Cas Lek Cesk; 1983 May; 122(20):628-31. PubMed ID: 6342789
[No Abstract] [Full Text] [Related]
23. Plafibride tolerance trial at increasing doses in healthy volunteers.
Dalmau J; Vicens B; Zapatero J; Bruseghini L
Arzneimittelforschung; 1981; 31(10a):1840-4. PubMed ID: 7198462
[TBL] [Abstract][Full Text] [Related]
24. [Therapy of ischemic ulcers of the lower extremities using plafibride].
Palou Monzo J; López-Delmás FJ
Angiologia; 1984; 36(6):273-8. PubMed ID: 6517385
[No Abstract] [Full Text] [Related]
25. Branched chain amino acid oxidation in cultured rat skeletal muscle cells. Selective inhibition by clofibric acid.
Pardridge WM; Casanello-Ertl D; Duducgian-Vartavarian L
J Clin Invest; 1980 Jul; 66(1):88-93. PubMed ID: 7400311
[TBL] [Abstract][Full Text] [Related]
26. The effect of amino acid derivative of clofibric acid (WKLB-5), and theophylline monoester of nicotinic acid (ME1) on the development of experimental atherosclerosis in rabbits.
Wójcicki J; Jaworska M; Samochowiec L; Hinek A
Pol J Pharmacol Pharm; 1986; 38(1):77-84. PubMed ID: 3509959
[TBL] [Abstract][Full Text] [Related]
27. [Experimental research on the action of a derivative from a p-chloropenoxyisobutyric acid series on lipid parameters].
Filip M; Hriscu A; Păduraru I; Rusu M
Rev Med Chir Soc Med Nat Iasi; 1986; 90(1):156-60. PubMed ID: 3764166
[No Abstract] [Full Text] [Related]
28. [Rhabdomyolysis under treatment by ciprofibrate in the nephrotic syndrome].
Baglin A; Lasserre N; Prinseau J; Lebas M
Therapie; 1987; 42(2):247-8. PubMed ID: 3617003
[No Abstract] [Full Text] [Related]
29. [Lipid therapy with etofibrate. Reduction of multiple risk factors with an active substance. Report of an international seminar. 8-11 November 1989, Houston, Texas].
Fortschr Med Suppl; 1990; 85():1-15. PubMed ID: 2338325
[No Abstract] [Full Text] [Related]
30. Hypolipemic activity of clofibrate-related compounds.
Metz G; Specker M
Arzneimittelforschung; 1975 Nov; 25(11):1686-92. PubMed ID: 1243074
[TBL] [Abstract][Full Text] [Related]
31. Plafibride tolerance trial in healthy volunteers.
Dalmau J; Vicens B; Zapatero J; Bruseghini L
Arzneimittelforschung; 1981; 31(10a):1845-9. PubMed ID: 7198463
[TBL] [Abstract][Full Text] [Related]
32. [Plafibride treatment of hyperlipidemias type II and IV].
Soler J; Vinzia C; Gómez JM; Morató J
Med Clin (Barc); 1984 May; 82(19):840-2. PubMed ID: 6738212
[No Abstract] [Full Text] [Related]
33. [Effect of bezafibrate on lipid and apoprotein levels in patients with idiopathic hypertriglyceridemia].
Naruszewicz M; Nowicka G; Szostak WB; Kłosiewicz-Latoszek L
Kardiol Pol; 1982; 25(7-8):527-31. PubMed ID: 7169740
[No Abstract] [Full Text] [Related]
34. Platelet antiaggregant activity of plafibride ex vivo in rat, dog and rabbit.
Bruseghini L; Vilageliu J; Freixes J
Arzneimittelforschung; 1981; 31(10a):1790-5. PubMed ID: 6797443
[TBL] [Abstract][Full Text] [Related]
35. [Hypolipidemic activity of glycine and its derivatives].
Ryzhenkov VE; Molokovskiĭ DS; Ioffe DV
Vopr Med Khim; 1984; 30(2):78-80. PubMed ID: 6740998
[TBL] [Abstract][Full Text] [Related]
36. The analysis of [14C]clofibric acid glucuronide and [14C]clofibric acid in plasma and urine using high-performance liquid chromatography.
Meffin PJ; Zilm DM
J Chromatogr; 1983 Nov; 278(1):101-8. PubMed ID: 6662867
[TBL] [Abstract][Full Text] [Related]
37. [Lipid-lowering effect of etofibrate, bezafibrate and xanthinol nicotinate in patients with hyperlipoproteinemias].
Machalke K; Djaja S; Richter E
Ther Ggw; 1982 May; 121(5):301-11. PubMed ID: 6953613
[No Abstract] [Full Text] [Related]
38. Bioavailability studies of etofibrate in rhesus monkeys.
Waller AR; Chasseaud LF; Taylor T; Schatton W
Arzneimittelforschung; 1985; 35(2):489-92. PubMed ID: 4039571
[TBL] [Abstract][Full Text] [Related]
39. Species differences in the metabolic conjugation of clofibric acid and clofibrate in laboratory animals and man.
Emudianughe TS; Caldwell J; Sinclair KA; Smith RL
Drug Metab Dispos; 1983; 11(2):97-102. PubMed ID: 6133730
[TBL] [Abstract][Full Text] [Related]
40. Activity of plafibride on erythrocyte deformability.
Vilageliu J; Freixes J; Bruseghini L
Arzneimittelforschung; 1983; 33(3):401-4. PubMed ID: 6683514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
